GlassScriptPhysician profile
Roberta H Lieber
NPI 1851716294
$497.58
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $250.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Abbvie INC. | $124.54 | 2021 | |
| Glaxosmithkline, LLC. | $56.69 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $40.99 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $35.81 | 2021-2022 | |
| Philips North America LLC | $29.64 | 2022 | |
| Amneal Pharmaceuticals LLC | $21.51 | 2022 | |
| Genentech USA, INC. | $19.35 | 2021 | |
| Currax Pharmaceuticals LLC | $17.63 | 2021 | |
| Pfizer INC. | $14.98 | 2021 | |
| Sanofi Pasteur INC. | $11.44 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Lieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.